Invention Grant
- Patent Title: Combination of lenalidomide and polypeptide construct, and uses thereof
-
Application No.: US14701628Application Date: 2015-05-01
-
Publication No.: US09636334B2Publication Date: 2017-05-02
- Inventor: Sarah L. Pogue , David S. Wilson , Anthony Gerard Doyle , Collette Jane Behrens
- Applicant: Teva Pharmaceuticals Australia Pty, Ltd
- Applicant Address: AU Macquarie Park, NSW
- Assignee: Teva Pharmaceuticals Australia Pty Ltd
- Current Assignee: Teva Pharmaceuticals Australia Pty Ltd
- Current Assignee Address: AU Macquarie Park, NSW
- Agency: Stradley Ronon Stevens & Young, LLP
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61K38/21 ; A61K31/454 ; C07K16/28 ; C07K14/56 ; A61K45/06

Abstract:
Methods for cancer treatment include administering to a cancer patient an anti-CD38 antibody-attenuated human IFN alpha-2b construct and lenalidomide or pomalidomide. Tumors that may be treated according to these methods include tumors which comprise CD-38 expressing tumor cells, including B-cell lymphoma, multiple myeloma, non-Hodgkin's lymphoma, chronic myelogenous leukemia, chronic lymphocytic leukemia, and acute lymphocytic leukemia.
Public/Granted literature
- US20150313965A1 Combination of Lenalidomide and Polypeptide Construct, and Uses Thereof Public/Granted day:2015-11-05
Information query